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PRELIMINARY AND SHORT REPORTS
ATJREOMYCIN EMPLOYED LOCALLY IN PAINFUL MOUTH ULCERATIONS
(ST0MATITIs APHTrIOSA oa PERIADENITIS MUCOSA NECEOTICA RECURRENS)
IRvING H. DISTELREIM. M.D. AND MARION B. SULZBERGER, M.D.
Aureomycin, the antibiotic derived from cultures of the mold known as Streptomyces
aureofaciens, has shown promise of being an effective chemotherapeutic agent in many
diseases produced by gram negative, gram positive and Rickettsial organisms. There have
been encouraging reports in the recent literature to show that Aureomycin may even prove
to be of value in the treatment of some viral diseases. Wong and Cox (1) in their experi-
ments found Aureomycin to have therapuetic activity orally, as well as parenterally, for
mice infected with psittacosis or lymphogranuloma venereum virus. Wright (2) et al., corro-
borated this clinically in a preliminary report on the treatment of lymphogranu-
loma venereum. The encouraging results they obtained may be even more significant, for
because of their laudably cautious approach with a new drug, their dosages (10-20 rug, daily)
were low according to more recent schedules. Braley and Sanders (3) in a preliminary report
showed effective results of Aureomycin against staphylococci, pneumococci, infiuenzal and
inclusion conjunctivitis. In a later report (4) infections produced by the diplococci of Morax
Axenfeld and E. Coli were also found to respond very favorably to treatment. The work of
Braley and Sanders is also of great interest as it is the first to show the possibilities of local
therapy with Aureomycin. Crooke (5) found Aureomycin effective against the Rickettsia
of Rocky Mounted Spotted Fever in a proven case. This was later corroborated by Ross (6)
et al., in a larger series of cases. Schoenbach (7) found Aureomycin to exert a beneficial
influence on the course of epidemic typhus (Brill's disease), another disease of Rickettsial
etiology. Spink (8) et al., found that brucellosis produced by Br. Melitensis underwent
dramatic remission while under Aureomycin therapy. Schoenbach and Bryer (9) found that
atypical non-bacterial pneumonia gave results which were promising. Finland, Collins, and
Paine, Jr. (10) showed beneficial results in treating a wide range of bacterial infections,
especially those produced by cocci, and most recently Woodward (11), et al., found that
Bacterium tularense was susceptible to Aureomycin. Thus the scope and efficacy of therapy
with Aureomycin is ever increasing as the reports continue to be published.
As dermatologists, we have been greatly interested in observing the efficacy of Aureo-
mycin, and in particular its usefulness when applied directly to the skin and/or accessible
mucous membranes. The following case is one which afforded an excellent opportunity for
this type of study.
CASE REPORT
1. L., a 39 year old white male was first seen in February 1947, at which time he gave a
history of having had painful ulcerated lesions of the buccal mucous membranes since the
fall of 1944. These ulcers were invariably covered with a grayish membrane. No history was
obtained of the ingestion of any drugs prior to the onset of these lesions, nor of any lesions
occurring elsewhere on the body. The clinical diagnosis of aphthous stomatitis or peria-
deriitis mucosa necrotica recurrens was made by several specialists. The patient felt that
periods of anxiety and emotional tension tended to precipitate the development of new
lesions. At one time he had received applications of gentian violet locally, and large doses
of many different vitamins and iron taken orally. Under this regimen he showed some im-
provement after two months. However the lesions never cleared completely. About one
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year after this he suffered an outbreak of new lesions, thus setting a pattern which repeated
itself several times, with the interval between remissions varying from time to time. Un-
fortunately no virus cultures or studies were attempted. No yeast and fungi could be demon-
strated on culture and smears failed to disclose Vincent's organisms. In addition to the
above described regime, therapy at various intervals consisted of vitamin B1, hydrogen
peroxide, sulfanilamide lozenges, milk of magnesia or sodium bicarbonate mouth washes,
penicillin lozenges, and glutamic acid and hydrochloride acid orally. None of the therapy
was of any significant benefit.
At the time of our first examination there was a deep irregular ulcer on the left buccal
mucosa surrounded by redundant tissue. On the lower lingual mucosa there was an irregular
depression. No characteristic odor was detected. Clinically this appeared to be a case of
periadenitis mucosa necrotica recurrens.
The patient was advised to avoid chocolate, nuts, shellfish, pork, iodides and bromides
and was given a mouth rinse of phenol 0.5%, benzocaine 3%, in nivea oil. A biopsy was,
taken which ruled out a papilloma, but a definite diagnosis was not made.
The patient appeared again on March 11, 1949 stating he had been "plagued" persistently
by the mouth lesions during the entire interim between visits. The most recent crop of new
lesions had developed only two weeks before. As the patient was from another city, he had
seen a local dermatologist since his last visit and had been given pyribenzamine tablets
orally, and a series of seven or eight smallpox vaccinations, with no noticeable result. Ex-
amination at this time revealed several superficially ulcerated lesions which were covered
with a grayish membrane and distributed as follows: (1) pea-sized on tip of tongue, (2)
dime-sized on right buccal mucosa, (3) bean-sized on inner gingival tissue below the first
lower right molar, and (4) several grouped lesions on mucous surface of lower lip extending
to the left buccal mucosa.
With a view to studying the local action, the patient was placed on a regimen of using
Aureomycin solution as a mouth rinse in the morning and evening, and dabbing each lesion
with the solution twice during the day. As the stability of Aureomycin in aqueous solution
at room temperature is poor, the patient was instructed to prepare a fresh solution daily.
The solution was prepared by dissolving a 50 mg. capsule in 50 cc of water (a %solution).
After a few applications, the patient found the process of dabbing each lesion too time con-
suming and inconvenient, and confined the treatment to rinsing his mouth four times daily.
None of the solution was knowingly swallowed.
RESULTS OF THERAPY
The most striking effect the patient noticed was the disappearance of pain and burning
oti the second day of treatment. Healing began after the second day of treatment, and con-
tinued unimpeded so that on the sixteenth day, only the outlines of the sites of healed lesions
were discernible. Older and newer lesions responded in the same way and equally well. The
patient stated that "nothing like this has occurred in the five years I have been plagued
with these sores—it has seemed miraculous to me".
As for toxicity, the patient felt drowsy on the first and second day. This disappeared com-
pletely thereafter. No other side effects were noted.
CONCLUSIONS
A case of painful and persistent recurrent oral ulcerations and necroses of five years
duration, clinically diagnosed as aphthous stomatitis or periadenitis mucosa ilecrotica re-
currens, and perhaps of viral or mixed etiology, was treated with mouth rinses of 0.5%
aqueous solution of Aureomycin. The response in this case was unquestionable, rapid, and
dramatic. This report is submitted in order to stimulate further studies with Aureomycin
in this type of refractory buccal disease and in other etiologically unclear but possibly viral
diseases, or mixed infections of the skin and mucous membranes.
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